FDA blasts Edenbridge over 'misleading' exhibit booth panel
The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessing the drugmaker's compliance with the rules on promoting prescription drugs in an exhibit booth panel.
The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessing the drugmaker's compliance with the rules on promoting prescription drugs in an exhibit booth panel.
